Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
NCT: NCT05837091 · RECRUITING
Brief Summary
Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.
Frequently Asked Questions
What is Low Sodium Oxybate in Patients With Idiopathic Hypersomnia?
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia is a clinical trial registered under NCT05837091. Current status: RECRUITING.
What is the status of NCT05837091?
The current status of NCT05837091 (Low Sodium Oxybate in Patients With Idiopathic Hypersomnia) is: RECRUITING.
When did Low Sodium Oxybate in Patients With Idiopathic Hypersomnia start?
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia started on 2024-02-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.